我省全方位支持医药产业创新发展

Group 1 - The pharmaceutical industry is a key emerging sector in the province, with a focus on regulatory reforms to enhance development [1] - Nine new policy documents have been issued this year to empower high-quality development in the pharmaceutical industry, including nine newly approved drug registration numbers and 19 traditional Chinese medicine formula granules [1] - A pilot program for optimizing drug supplementary application review and approval procedures will be established in Liaoning, significantly reducing technical review timelines from 200 working days to 60 [1] Group 2 - The province supports innovation in pharmaceuticals and medical devices by optimizing review and approval processes, which has led to a reduction of over 3,600 working days in enterprise inspections [2] - New policies have adjusted industry entry conditions, such as reducing the required warehouse area for new pharmaceutical wholesale enterprises by 50%, resulting in cost savings for companies [2] - The implementation of remote pharmaceutical services has helped reduce operational costs for enterprises by approximately 34 million yuan annually [2] Group 3 - The province has introduced a new safety assessment standard for ordinary cosmetics, reducing testing costs by over 60%, leading to a 950% increase in the submission of complete safety assessment materials [3] - Collaborative efforts have been made to establish medical device innovation service stations, providing comprehensive support for enterprises in policy consultation, application guidance, and training [3] - The initiative aims to enhance the local business environment and attract investment, promoting the high-quality development of the medical device industry [3]